Heart failure with preserved ejection fraction (HFpEF)
HFpEF is one of the most common forms of heart failure, mainly affecting older people, and there are currently few effective therapies available. The DZHK studies the causes and progression of the disease, improves diagnosis and develops new approaches for more targeted treatments.
Why this area matters
Many patients with heart failure have a preserved ejection fraction. Symptoms are often non-specific, and comorbidities such as hypertension, obesity or diabetes can overlap with the condition. Standard therapies are of limited benefit. A more precise classification is needed so that patients can be identified and treated more appropriately and earlier.
Our research approach
We systematically characterise HFpEF using clinical data, imaging, biomarkers and digital measurement tools. This enables us to distinguish patient groups more effectively and assess risk trajectories. The results inform decision-support tools that enhance diagnosis and treatment planning.
Another focus is the connection between mechanisms and clinical application. We will test findings on vascular function, myocardial stiffness, inflammation, and metabolism in studies. This will allow us to develop targeted strategies and to evaluate their benefits for patient care.
Spokespersons
- Gabriele Schiattarella, Berlin
- Eike Nagel, RheinMain
- Sandy Engelhardt, Heidelberg/Mannheim
Are you conducting research within or outside the DZHK and would like to connect with this focus area? Please contact: